Merck & Co.
AWARDS
NEWS
Here’s a look at recent clinical trial pauses around the biopharma industry.
Merck and Eisai announced today that they have new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
It was another busy week for clinical trial updates and news. Here’s a look.
JOBS
IN THE PRESS